WO2005075016A1 - 経皮薬物投与装置用インタフェース - Google Patents
経皮薬物投与装置用インタフェース Download PDFInfo
- Publication number
- WO2005075016A1 WO2005075016A1 PCT/JP2005/001525 JP2005001525W WO2005075016A1 WO 2005075016 A1 WO2005075016 A1 WO 2005075016A1 JP 2005001525 W JP2005001525 W JP 2005001525W WO 2005075016 A1 WO2005075016 A1 WO 2005075016A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interface
- drug administration
- skin
- administration device
- transdermal drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 239000000919 ceramic Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 49
- 238000001647 drug administration Methods 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 35
- 239000010410 layer Substances 0.000 description 8
- -1 polybutylene Polymers 0.000 description 8
- 239000000463 material Substances 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 238000004512 die casting Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229920006248 expandable polystyrene Polymers 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229920003049 isoprene rubber Polymers 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Definitions
- the present invention relates to an interface for a transdermal drug administration device for administering a drug through the skin, and more particularly to an interface for a transdermal drug administration device having a projection capable of piercing the skin.
- a method is generally used in which a patch containing a drug is applied to the skin and the drug is administered by penetrating the drug into the skin.
- iontophoresis Journal of Pharmaceutical Sciences, vol. 76, p. 341 (1987)
- electoporation Tokuhei 3-502416, Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 10504-10508, 1993
- Both iontophoresis and electoporation are expected to be used as a method to enhance the absorption of drugs through the skin or transmucosally.
- Patent Document 1 proposes a device for enhancing percutaneous flow by mechanically piercing the skin before releasing a transdermal drug.
- the device comprises a sheet having a plurality of openings, a plurality of microblades integral therewith and extending downwardly therefrom, and means for anchoring the device to a body surface.
- This seeks to provide a reproducible, high-yield, low-cost device suitable for improving skin attachment while minimizing skin irritation.
- a similar device is also proposed in Patent Document 2.
- Patent Document 1 Japanese Patent Publication No. 2000-512529
- Patent Document 2 JP 2001-506904 A
- Patent Document 3 proposes a device having a drug administration device provided with a large number of drug administration needles for administering a drug through the skin or mucous membrane by iontophoresis drive.
- the device comprises a needle support and a skin or mucous membrane contacting side of the needle support.
- a plurality of drug administration needles are provided, and the tip of the drug administration needle located near the center of the needle support protrudes from the tip of the drug administration needle located at the periphery of the needle support. It is configured to This makes it possible to reliably puncture the fine needle of the administration device into the administration site during drug administration by iontophoresis drive, and to distribute the current appropriately to reduce irritation to the skin.
- the aim is to provide a device that can easily control the dosage.
- Patent Document 3 JP 2003-93521 A
- the microblade for piercing the skin in the devices of Patent Documents 1 and 2 described above is formed by bending a sheet having an opening at the opening. .
- the microblade is flat and cannot be reliably pierced by the skin.
- Microblades have the problem of requiring extremely fine and high-precision machining (bunching).
- the flat plate-shaped member of the needle support main body has a lattice shape as a whole, a drug passage is formed, and a drug administration needle is provided at each intersection of the lattice. Have been.
- the object is to provide a plurality of conical or pyramid-shaped projections arranged in a two-dimensional shape capable of piercing the skin, and a plurality of openings capable of transmitting a drug arranged corresponding to each of the projections.
- This is achieved by an interface for a transdermal drug administration device having a flat plate with a portion, wherein each of the openings is disposed in close proximity to a corresponding projection.
- a groove may be provided on the flat plate between the opening and the corresponding protrusion to guide the drug to the opening force and the corresponding protrusion.
- the height of the projection is, for example, 100 to 700 m
- the diameter of the lower bottom of the projection is, for example, 30 to 200 m
- the diameter of the opening is, for example, 50 to 2000 / zm.
- the ratio of the number of the openings to the number of the protrusions is preferably 1: 1 to 1: 2.
- the flat plate may be made of metal or ceramic.
- FIG. 1 is a cross-sectional view showing an example of a transdermal drug administration device using an interface for a transdermal drug administration device according to the present invention.
- FIG. 2 is a view showing an example of an interface for a transdermal drug administration device according to the present invention, wherein (a) is a perspective view and (b) is a cross-sectional view taken along line AB of (a).
- FIG. 3 is a plan view of the interface for the transdermal drug administration device in FIG. 2.
- FIG. 4 is a plan view showing another example of an interface for a transdermal drug administration device according to the present invention.
- FIG. 1 is a cross-sectional view showing one example of a transdermal drug administration device using the interface for a transdermal drug administration device according to the present invention.
- the transdermal drug administration device of this example includes a support 1, a drug-containing layer 2 disposed on the support 1, a wall material 3 disposed on the support 1 so as to surround the drug-containing layer 2, An adhesive layer 4 provided on the skin-adhering side of the support 1 and a transdermal drug administration device interface 5 provided on the skin-adhering side of the drug-containing layer 2 are provided.
- the drug-containing layer 2 holds, for example, a drug in a liquid state.
- the interface 5 for the transdermal drug administration device includes a plurality of conical or pyramid-shaped projections 6 capable of piercing the skin, and a plurality of drug-dispensing devices arranged corresponding to the projections. And a flat plate 8 having an opening 7.
- the transdermal drug administration device interface 5 is applied to the skin when applied, pressed against the skin from above the device, and adhered to the skin by the adhesive layer 3. Then, the skin (the stratum corneum) is perforated by the plurality of projections 6 provided on the interface 5 for the transdermal drug administration device. As a result, the liquid drug from the drug-containing layer 2 passes through the plurality of openings 7 provided in the flat plate 8 and exits to the skin. The liquid drug that has flowed out flows to the root end of the plurality of protrusions 6 and penetrates into the body through the holes formed in the skin by the protrusions 6.
- transdermal drug administration device of the present example, the following components can be used.
- An impermeable material is selected as the support, and examples thereof include polyolefin, polyurethane, polystyrene, rubber, EVA, PVC, and PET.
- a water-impermeable material is selected, for example, foamed polyolefin (PE, PP, etc.), foamed polyurethane, foamed polystyrene, foamed rubber (polybutylene, etc.), foamed EVA, foamed PVC, etc.
- foamed polyolefin PE, PP, etc.
- foamed polyurethane foamed polystyrene
- foamed rubber foamed rubber
- foamed EVA foamed PVC, etc.
- foamed polyolefin foamed polyolefin.
- the adhesive layer includes, for example, natural rubber, styrene isoprene styrene block copolymer, styrene butadiene rubber, styrene isoprene rubber, polyisobutylene, polyisoprene, polyatalylate, and silicone rubber. , Polyatarilate.
- the drug-containing layer may be any layer that can hold the drug in a liquid state.
- a nonwoven fabric made of polyester (polyethylene terephthalate), polysaccharide or cellulose derivative (rayon, cotton), polyamide (nylon), Porous material such as woven fabric, gauze or sponge Body or hydrophilic polymer (agar, agarose, alginic acid, xanthan gum, guar gum, dextran, dextrin, pullulan, chitosan, gelatin, carboxyvinyl polymer, polyacrylate, carboxymethylcellulose salt, polyoxyalkylene, polybutyl) Forces such as alcohol, polybutylpyrrolidone, polyacrylamide) and ion-exchange resins (amber lite, diaion, cholestyramine).
- non-woven fabric mainly composed of rayon.
- various drugs can be selected according to the purpose of treatment.
- the type of drug and the type of salt, and the indication of each drug are particularly limited.
- antibiotics, antifungal agents, antitumor agents, inotropic agents, arrhythmic treatment agents, vasodilators, antihypertensive agents, diuretics, antihypertensive diuretics, cardiovascular agents, antiplatelet agents, hemostatic agents, antihyperlipidemia Antihypertensive, antipyretic, analgesic, anti-inflammatory, antirheumatic, relaxant, antitussive, antiulcer, sedative, antiepileptic, antidepressant, antiallergic, antidiabetic, antituberculosis, hormone Drugs, narcotic antagonists, bone resorption inhibitors, angiogenesis inhibitors, local anesthetics and the like are used.
- the transdermal drug administration device is shown as a normal patch, but is not limited to this.By adding an electrode to this example, an ion-based administration method using electrical energy can be used. It can also be used in devices for tophoresis and electoral opening.
- FIG. 2 is a view showing an example of an interface for a transdermal drug administration device according to the present invention, wherein (a) is a perspective view and (b) is a cross-sectional view taken along line AB of (a).
- FIG. 3 is a plan view of the interface for the transdermal drug administration device in FIG.
- the interface 5 for a transdermal drug administration device has a flat plate 8.
- the flat plate 8 includes a plurality of conical or pyramidal projections 6 arranged two-dimensionally so that the skin can be pierced, and a plurality of openings 7 arranged corresponding to each projection and capable of transmitting a drug. Is provided.
- each opening 7 is arranged close to the corresponding projection 6 respectively.
- Proximity placement means that the distance between a particular protrusion and its corresponding opening is smaller than the distance between that particular protrusion and its non-corresponding opening, and as a result Means that the portion and the corresponding opening are arranged close to each other.
- a plurality of protrusions 6 and a plurality of openings 7 are alternately arranged in a square lattice.
- the number of protrusions 6 and openings 7 is 1: 1. Attention is now focused on the four adjacent protrusions 6a-6d and the opening 7a surrounded by them.
- a straight line passing through the center of each protrusion 6a-6d and the opening 7a is drawn in the vertical and horizontal directions of the square lattice.
- the line segments L1 and L2 are obtained in the horizontal direction
- the line segments L3 and L4 are obtained in the vertical direction.
- the expression that the opening 7a is disposed close to the corresponding protrusion 6a means that the relationship of L1ZL2 and L3ZL4 is satisfied, but this relationship is LlZL2 ⁇ 0.9 and L3 It is more preferable that /L4 ⁇ 0.9.
- L1 / L2 is more preferably 0.8 and L3ZL4 is more preferably 0.8.
- each opening is arranged close to the corresponding protrusion, for example, in Fig. 3, the drug that has passed through the corresponding opening 7a tends to flow into the protrusion 6a, and similarly, Drugs that have passed through the corresponding openings 7b-7d are more likely to flow into the other protrusions 6b-6d.
- the drug can be almost uniformly supplied from each projection into the body through the skin.
- the protruding portion is formed in a conical or pyramidal shape, even if the transdermal drug administration device is pressed against the skin, the skin can be reliably perforated without the protruding portion bending. As a result, the drug can be satisfactorily supplied from each projection into the body through the skin.
- FIG. 4 is a plan view showing another example of the interface for a transdermal drug administration device according to the present invention.
- a plurality of protrusions 6 and a plurality of openings 7 are arranged as shown in the figure.
- the number of protrusions 6 and openings 7 is 2: 1. Attention is now focused on the four adjacent protrusions 6aa, 6ab, 6ba, 6bb, the opening 7a surrounded by them, and the adjacent opening 7b.
- a straight line passing through the center of each protrusion 6aa, 6ab, 6ba, 6bb and the opening 7a, 6b is drawn in the vertical, horizontal, and oblique directions.
- the line segments Lll, L12, and L13 are obtained in the horizontal direction
- the line segments L21 and L22 are obtained in the vertical direction
- the line segment L31 is obtained in the oblique direction.
- LllZL12 l power L31ZL13 ⁇ 0.9 power L21ZL22 0 0.9 is preferable
- LllZL12 l power L31ZL13 0 0.8 power L21ZL22 0 0.8 preferable.
- the drug that has passed through the opening 7a corresponding to the pair of projections 6aa and 6ab is likely to flow, and the other pair of projections similarly has the opening corresponding thereto.
- Drugs that have passed through each flow more easily.
- the drug can be almost uniformly supplied from each projection into the body through the skin.
- the projection since the projection is formed in a conical or pyramidal shape, even if the transdermal drug administration device is pressed against the skin, the projection can be reliably perforated without bending the projection. As a result, the drug can be satisfactorily supplied from each projection into the body through the skin.
- Plates include Ti, Ti alloy, Ag, SiO, Pt, stainless steel, carbon, hydroxya
- Metals such as tight, alloys or ceramics, or polystyrene, polyester, p
- Plastics such as MMA, ABS, PP, PE, PLA (polylactic acid), PGA (polyglycolic acid), PLGA (lactic acid-polyglycolic acid copolymer), and HEMA can be used.
- the above materials can be used alone or as a composite material, and can be applied to an appropriate electrochemically and mechanically favorable interface characteristic by coating.
- the thickness D1 of the flat plate is preferably 0.1 to 3. Omm.
- the projection can be formed by processing the flat plate.
- a processing method for example, etching, die casting, or the like can be used.
- the shape of the projection is preferably a conical shape or a pyramid shape, and the tip is desirably sharp.
- the conical shape or the pyramid shape is not limited to the conical shape or the pyramid shape, but is a broad concept showing a similar shape, and the taper continuously or stepwise tapers downwardly with the bottom force of the protrusion. All shapes are included.
- the height H of the projection is preferably 100 to 700 m. Bottom bottom of protrusion
- the diameter D2 is preferably 30 to 200 ⁇ m.
- the number of projections formed on the flat plate is preferably 1000 to 2000 Z.
- the pitch P between the projections is preferably, for example, 200 to 600 m.
- the opening is a hole formed by cutting the flat plate.
- a processing method for example, etching, die casting, laser processing, or the like can be used.
- the shape of the opening is a force such as a circle or a polygon, but is not limited thereto.
- the diameter D3 of the opening is preferably 50 to 2000 m.
- the number of openings formed on a flat plate is preferably 1000 to 2000 Z.
- the ratio of the number of openings to the number of protrusions is preferably 1: 1 to 1: 2.
- the protruding portion has a conical shape
- the area of the lower bottom (per unit cell) is Sl
- the area of the opening (per unit cell) is S2
- the area of the unit cell is S3, It is preferable that the following relationship be satisfied in order to administer the drug satisfactorily.
- the skin can be reliably perforated, and the drug can be passed through the opening and the projection of the plate containing the drug. It was able to penetrate the skin well (confirmed by pigmentation of the skin with the pigment).
- the interface for a transdermal drug administration device according to the present invention can be used in the medical field, and can supply a drug to the body through the skin almost uniformly and satisfactorily with a plurality of projections.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicinal Preparation (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005517711A JP4832082B2 (ja) | 2004-02-03 | 2005-02-02 | 経皮薬物投与装置用インタフェース |
US10/588,168 US7914813B2 (en) | 2004-02-03 | 2005-02-02 | Interface for transdermal drug administration device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-026327 | 2004-02-03 | ||
JP2004026327 | 2004-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005075016A1 true WO2005075016A1 (ja) | 2005-08-18 |
Family
ID=34835843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001525 WO2005075016A1 (ja) | 2004-02-03 | 2005-02-02 | 経皮薬物投与装置用インタフェース |
Country Status (3)
Country | Link |
---|---|
US (1) | US7914813B2 (ja) |
JP (1) | JP4832082B2 (ja) |
WO (1) | WO2005075016A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010016218A1 (ja) * | 2008-08-05 | 2010-02-11 | 国立大学法人 香川大学 | マイクロニードルとその冶具 |
WO2010110397A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人 香川大学 | マイクロニードルおよびその製造方法と金型 |
CN106999702A (zh) * | 2014-12-05 | 2017-08-01 | 久光制药株式会社 | 微针装置系统 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2729404C (en) * | 2008-06-30 | 2016-09-27 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device and method for enhancing the efficacy of influenza vaccine using microneedle device |
KR101033513B1 (ko) * | 2009-01-20 | 2011-05-09 | (주)마이티시스템 | 미세바늘을 이용한 유용성분 피부전달용 용기 |
EP2403482B1 (en) | 2009-03-04 | 2017-12-27 | Emplicure AB | Abuse resistant formulation |
ES2673196T3 (es) | 2009-05-08 | 2018-06-20 | Emplicure Ab | Composición para la administración sostenida de fármacos que comprende aglutinante geopolimérico |
ES2691259T3 (es) * | 2009-06-10 | 2018-11-26 | Hisamitsu Pharmaceutical Co., Inc. | Dispositivo de microagujas |
EP2457592B1 (en) | 2009-07-23 | 2020-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle array |
WO2011105496A1 (ja) | 2010-02-24 | 2011-09-01 | 久光製薬株式会社 | マイクロニードルデバイス |
CN102985131B (zh) | 2010-04-28 | 2016-06-29 | 金伯利-克拉克环球有限公司 | 用于递送siRNA的医疗装置 |
WO2011135533A2 (en) | 2010-04-28 | 2011-11-03 | Kimberly-Clark Worldwide, Inc. | Nanopatterned medical device with enhanced cellular interaction |
US9522263B2 (en) | 2010-04-28 | 2016-12-20 | Kimberly-Clark Worldwide, Inc. | Device for delivery of rheumatoid arthritis medication |
US9586044B2 (en) | 2010-04-28 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Method for increasing the permeability of an epithelial barrier |
NO2613784T3 (ja) | 2010-09-07 | 2018-05-12 | ||
US8696637B2 (en) | 2011-02-28 | 2014-04-15 | Kimberly-Clark Worldwide | Transdermal patch containing microneedles |
WO2013051568A1 (ja) | 2011-10-06 | 2013-04-11 | 久光製薬株式会社 | アプリケータ |
KR20140079429A (ko) | 2011-10-27 | 2014-06-26 | 킴벌리-클라크 월드와이드, 인크. | 생체활성 제제를 전달하기 위한 이식형 기구 |
US9550053B2 (en) | 2011-10-27 | 2017-01-24 | Kimberly-Clark Worldwide, Inc. | Transdermal delivery of high viscosity bioactive agents |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
CN108853709B (zh) * | 2018-04-27 | 2019-06-18 | 清华大学 | 柔性水凝胶微针贴片及其制备方法 |
US11638809B2 (en) | 2019-06-28 | 2023-05-02 | Passport Technologies, Inc. | Triptan microporation delivery system |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002079499A (ja) * | 2000-09-08 | 2002-03-19 | Terumo Corp | 針形状物の作製方法および作製された針 |
WO2002032480A2 (en) * | 2000-10-16 | 2002-04-25 | The Procter & Gamble Company | Microstructures for delivering a composition cutaneously to skin |
WO2002094368A1 (en) * | 2000-10-26 | 2002-11-28 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
JP2003093521A (ja) * | 2001-09-26 | 2003-04-02 | Terumo Corp | 薬剤投与具及び薬剤投与装置 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
ITPD20020138A1 (it) * | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima. |
-
2005
- 2005-02-02 US US10/588,168 patent/US7914813B2/en active Active
- 2005-02-02 JP JP2005517711A patent/JP4832082B2/ja active Active
- 2005-02-02 WO PCT/JP2005/001525 patent/WO2005075016A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002079499A (ja) * | 2000-09-08 | 2002-03-19 | Terumo Corp | 針形状物の作製方法および作製された針 |
WO2002032480A2 (en) * | 2000-10-16 | 2002-04-25 | The Procter & Gamble Company | Microstructures for delivering a composition cutaneously to skin |
WO2002094368A1 (en) * | 2000-10-26 | 2002-11-28 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
JP2003093521A (ja) * | 2001-09-26 | 2003-04-02 | Terumo Corp | 薬剤投与具及び薬剤投与装置 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010016218A1 (ja) * | 2008-08-05 | 2010-02-11 | 国立大学法人 香川大学 | マイクロニードルとその冶具 |
JP5521147B2 (ja) * | 2008-08-05 | 2014-06-11 | 国立大学法人 香川大学 | マイクロニードルとその冶具 |
WO2010110397A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人 香川大学 | マイクロニードルおよびその製造方法と金型 |
JP2010247535A (ja) * | 2009-03-25 | 2010-11-04 | Kagawa Univ | マイクロニードルおよびその製造方法と金型 |
CN106999702A (zh) * | 2014-12-05 | 2017-08-01 | 久光制药株式会社 | 微针装置系统 |
US10589077B2 (en) | 2014-12-05 | 2020-03-17 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device system |
Also Published As
Publication number | Publication date |
---|---|
US20070123837A1 (en) | 2007-05-31 |
JPWO2005075016A1 (ja) | 2007-10-11 |
US7914813B2 (en) | 2011-03-29 |
JP4832082B2 (ja) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4832082B2 (ja) | 経皮薬物投与装置用インタフェース | |
EP1737357B1 (en) | Transdermal delivery device | |
US7658728B2 (en) | Microneedle array, patch, and applicator for transdermal drug delivery | |
US20070250018A1 (en) | Transdermal Drug Administration System with Microneedles | |
JP4955634B2 (ja) | 薬剤投与具 | |
EP1035889B1 (en) | Device for enhancing transdermal agent flux | |
AU757230B2 (en) | Device for enhancing transdermal agent flux | |
US11766548B2 (en) | Phototherapeutic needle patches and methods of manufacturing the same | |
JP4647863B2 (ja) | 薬剤投与具及び薬剤投与装置 | |
JP2003535625A (ja) | 物質を抜き取り又は投与するための皮膚透過性強化装置及びその装置を製造するための方法 | |
JP2009508595A (ja) | 界面動電送出システム及びその方法 | |
WO2007091608A1 (ja) | マイクロニードル付き経皮薬物投与装置 | |
CN203090241U (zh) | 滚轮微针工具 | |
EP3701997B1 (en) | High-density microneedle | |
JP6900468B2 (ja) | マイクロニードル | |
TWI787652B (zh) | 微型針片材及施作器 | |
JP4935391B2 (ja) | 薬物輸送デバイス | |
MXPA00005761A (en) | Device for enhancing transdermal agent flux | |
MXPA00005725A (es) | Dispositivo para aumentar el flujo transdermico de agentes | |
MX2008003830A (es) | Sistema de suministro electrocinetico y metodos para el mismo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517711 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007123837 Country of ref document: US Ref document number: 10588168 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10588168 Country of ref document: US |